colorectal neoplasms

Summary

Summary: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Top Publications

  1. Ueno H, Hase K, Hashiguchi Y, Shimazaki H, Tanaka M, Miyake O, et al. Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters. Am J Surg Pathol. 2014;38:197-204 pubmed publisher
    ..40 for Grade(AJCC) and 0.52 for Grade(PDC). Grade(PDC) has a robust prognostic power and promises to be of sufficient clinical value to merit implementation as a site-specific grading system in CRC...
  2. Stock C, Hoffmeister M, Birkner B, Brenner H. Inter-physician variation in follow-up colonoscopies after screening colonoscopy. PLoS ONE. 2013;8:e69312 pubmed publisher
    ..Surveillance is an integral part of the colorectal cancer (CRC) screening process. We aimed to investigate inter-physician variation in follow-up procedures after screening colonoscopy in an opportunistic CRC screening program...
  3. Mazard T, Causse A, Simony J, Leconet W, Vezzio Vié N, Torro A, et al. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. Mol Cancer Ther. 2013;12:2121-34 pubmed publisher
    ..In conclusion, our results show that sorafenib can suppress resistance to irinotecan and suggest that sorafenib could be used to overcome resistance to irinotecan-based chemotherapies in CRC, particularly in KRAS-mutated tumors...
  4. Takahashi Y, Sawada G, Sato T, Kurashige J, Mima K, Matsumura T, et al. Microarray analysis reveals that high mobility group A1 is involved in colorectal cancer metastasis. Oncol Rep. 2013;30:1488-96 pubmed publisher
    ..The present study strongly supports the clinical significance of HMGA1 expression as a predictive indicator of lymph node metastasis in CRC cases, even in submucosal invasive cases which could be cured by local resection...
  5. Imperiale T, Ransohoff D, Itzkowitz S, Levin T, Lavin P, Lidgard G, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287-97 pubmed publisher
    ..An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening...
  6. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104-17 pubmed publisher
    ..Progress in reducing colorectal cancer death rates can be accelerated by improving access to and use of screening and standard treatment in all populations...
  7. Brenner H, Kloor M, Pox C. Colorectal cancer. Lancet. 2014;383:1490-1502 pubmed publisher
    ..Screening has been shown to reduce colorectal cancer incidence and mortality, but organised screening programmes are still to be implemented in most countries...
  8. Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2:50-6 pubmed publisher
    ..The results thus indicated a potential for aspirin to reduce colorectal adenoma development in patients with FAP, but careful follow-up is needed to avoid or rapidly counter severe adverse effects...
  9. Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208-15 pubmed publisher
    ..Here we present overall survival data after long-term follow-up...

More Information

Publications62

  1. Tofthagen C, Donovan K, Morgan M, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21:3307-13 pubmed publisher
    ..35, p?=?0.0004) and interference with activities(r?=?0.52, p?<?0.0001). HRQOL was significantly associated with peripheral neuropathy and interference with activities. ..
  2. Kuijpers A, Mirck B, Aalbers A, Nienhuijs S, de Hingh I, Wiezer M, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20:4224-30 pubmed publisher
    ..This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol...
  3. Chao S, Ying J, Liew G, Marshall W, Liew C, Burakoff R. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study. J Exp Clin Cancer Res. 2013;32:44 pubmed publisher
    ..A minimally invasive test that can detect both left-sided and right-sided lesions could increase the effectiveness of screening colonoscopy by revealing the potential presence of neoplasms in the right-sided "blind spot"...
  4. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151-6 pubmed publisher
    ..No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P(interaction) > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification...
  5. Chung A, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19:1114-23 pubmed publisher
    ..These findings indicate that IL-17 promotes tumor resistance to VEGF inhibition, suggesting that immunomodulatory strategies could improve the efficacy of anti-angiogenic therapy...
  6. Thierry A, Mouliere F, El Messaoudi S, Mollevi C, Lopez Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430-5 pubmed publisher
    ..CfDNA was detected in 100% of patients with mCRC. This study shows that liquid biopsy through cfDNA analysis could advantageously replace tumor-section analysis and expand the scope of personalized medicine for patients with cancer. ..
  7. Di Rosa M, Malaguarnera M, Zanghi A, Passaniti A, Malaguarnera L. Vitamin D3 insufficiency and colorectal cancer. Crit Rev Oncol Hematol. 2013;88:594-612 pubmed publisher
    ..The insights derived from these mechanisms may aid in designing new uses for this hormone and its non-hypercalcemic derivatives in the treatment and/or prevention of CRC...
  8. Ma X, Zhang B, Zheng W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut. 2014;63:326-36 pubmed publisher
    ..These genetic variants, if confirmed, may explain approximately 5% of familial CRC risk. ..
  9. Stegeman I, de Wijkerslooth T, Stoop E, van Leerdam M, Dekker E, van Ballegooijen M, et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut. 2014;63:466-71 pubmed publisher
    ..We explored the use of a risk prediction model in CRC screening...
  10. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013;4:1399-415 pubmed
    ..Therefore, this regulation may be potentially relevant for future diagnostic and therapeutic approaches. ..
  11. Suzuki Y, Yamaguchi T, Matsumoto H, Nakano D, Honda G, Shinoura N, et al. Prognostic factors and treatment effects in patients with curatively resected brain metastasis from colorectal cancer. Dis Colon Rectum. 2014;57:56-63 pubmed publisher
    ..Colorectal cancer infrequently causes brain metastasis, and the prognosis is poor...
  12. Vauthey J, Zimmitti G, Kopetz S, Shindoh J, Chen S, Andreou A, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619-26; discussion 626-7 pubmed publisher
    ..To determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy...
  13. Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, et al. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia. 2013;15:1086-99 pubmed
    ..Detection of onco-miR-130b and its association with PPAR? may be useful as a prognostic biomarker. Its targeting in vivo should be evaluated as a novel effective therapeutic tool against CRC...
  14. Kraus S, Nabiochtchikov I, Shapira S, Arber N. Recent advances in personalized colorectal cancer research. Cancer Lett. 2014;347:15-21 pubmed publisher
    ..We here review currently known molecular biomarkers used for the personalized treatment of colorectal cancer. ..
  15. Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105:1852-61 pubmed publisher
  16. Douillard J, Oliner K, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023-34 pubmed publisher
    ..Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy...
  17. Mills K, Bellows C, Hoffman A, Kelly T, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013;56:1304-19 pubmed publisher
    ..Diabetes mellitus is associated with an increased incidence of colorectal cancer, but the impact of diabetes mellitus on colorectal cancer prognosis is not clear...
  18. Barresi V, Bonetti L, Ieni A, Branca G, Baron L, Tuccari G. Histologic grading based on counting poorly differentiated clusters in preoperative biopsy predicts nodal involvement and pTNM stage in colorectal cancer patients. Hum Pathol. 2014;45:268-75 pubmed publisher
    ..In view of its good reproducibility, accuracy, and predictive value on the anatomical extent of the disease, it may be taken into account for decision-making in colorectal cancer treatment. ..
  19. Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol. 2013;31:4562-8 pubmed publisher
    ..Using this approach allows questions regarding efficacy and safety of multiple novel therapies to be answered in a relatively quick and efficient manner, while also allowing for the assessment of biomarkers to help target treatment. ..
  20. Perna L, Hoffmeister M, Schöttker B, Arndt V, Haug U, Holleczek B, et al. Vitamin D receptor polymorphism and colorectal cancer-specific and all-cause mortality. Cancer Epidemiol. 2013;37:905-7 pubmed publisher
    ..The vitamin D receptor (VDR) gene is present in colorectal cancer (CRC) cells and its genetic variants have been associated with an increased risk of CRC. The association with colorectal cancer prognosis remains widely unexplored...
  21. Mouradov D, Domingo E, Gibbs P, Jorissen R, Li S, Soo P, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013;108:1785-93 pubmed publisher
    ..It is not known which of MSI, CIN, and the specific gene mutations are primary predictors of survival...
  22. Barresi V, Branca G, Ieni A, Reggiani Bonetti L, Baron L, Mondello S, et al. Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. Virchows Arch. 2014;464:655-62 pubmed publisher
    ..The combination of this parameter with SM invasion depth may allow identifying most of the pT1 CRC with nodal metastases. ..
  23. Gollub M, Grewal R, Panu N, Thipphavong S, Sohn M, Zheng J, et al. Diagnostic accuracy of ¹?F-FDG PET/CT for detection of advanced colorectal adenoma. Clin Radiol. 2014;69:611-8 pubmed publisher
    ..To determine the accuracy of 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET) in the detection of advanced colorectal adenomas...
  24. Kim H, Huh J, Jung T, Kim I, Kim H, Jung S, et al. Clinical outcome with gamma-knife surgery or surgery for brain metastases from colorectal cancer. J Clin Neurosci. 2013;20:1417-21 pubmed publisher
    ..Surgery for brain metastasis from CRC is more advantageous in local control and neurologic symptom palliation than GSK. In multivariate analysis, overall survival was associated with controlled primary tumor and solitary metastasis...
  25. Budinska E, Popovici V, Tejpar S, D ario G, Lapique N, Sikora K, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231:63-76 pubmed publisher
    ..Original microarray data were uploaded to the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/) under Accession Nos E-MTAB-990 and E-MTAB-1026...
  26. Bullock M, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, et al. FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. Br J Cancer. 2013;109:387-94 pubmed publisher
    ..To clarify its role in human colorectal cancer (CRC) progression, we examined in vivo FOXO3 expression at key points of the metastatic cascade...
  27. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134:552-62 pubmed publisher
    ..Classification based on molecular subtypes made it possible to expand and improve CRC classification beyond standard molecular and immunohistochemical assessment and might help in the future to guide treatment in CRC patients. ..
  28. De Bruijn K, Arends L, Hansen B, Leeflang S, Ruiter R, van Eijck C. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013;100:1421-9 pubmed publisher
    ..This study investigated the association between DM and cancer incidence and cancer-specific mortality in patients with breast and colorectal carcinoma...
  29. Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg J. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer. 2014;50:40-9 pubmed publisher
    ..Two studies dealt with the CE of panitumumab. The analysis of sequential regimes and the direct comparison of two MoABs were analysed by only one study each. The quality of the included studies was high with the exception of one study...
  30. Cheng I, Kocarnik J, Dumitrescu L, Lindor N, Chang Claude J, Avery C, et al. Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia. Gut. 2014;63:800-7 pubmed publisher
    ..In a large-scale study, we examined 171 SNPs previously associated with 18 different cancers for their associations with colorectal cancer...
  31. Zackular J, Baxter N, Iverson K, Sadler W, Petrosino J, Chen G, et al. The gut microbiome modulates colon tumorigenesis. MBio. 2013;4:e00692-13 pubmed publisher
  32. Mege D, Ouaissi M, Fuks D, Metellus P, Peltier J, Dufour H, et al. Patients with brain metastases from colorectal cancer are not condemned. Anticancer Res. 2013;33:5645-8 pubmed
    ..They usually occur in advanced stages of the disease and their prognosis is poor. The aim of this study was to assess the impact of surgical resection of BMs from colorectal cancer in terms of overall survival...
  33. Duffy M, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134:2513-22 pubmed publisher
    ..For patients with suspected GIST, determination of KIT protein should be used as a diagnostic aid, while KIT mutational analysis may be used for treatment planning in patients with diagnosed GISTs...
  34. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077-1085 pubmed publisher
    ..The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer. F Hoffmann-La Roche. ..
  35. Li Y, Lu Y, Li C, Yuan P, Lin S. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis. DNA Cell Biol. 2014;33:455-62 pubmed publisher
    ..74-1.90, p=0.485). Our findings provide empirical evidence that CDH1 promoter methylation may play an important role in colorectal carcinogenesis. Thus, CDH1 promoter methylation may be a useful biomarker for the early diagnosis of CRC. ..
  36. John S, Robinson S, Rehman S, Harrison B, Vallance A, French J, et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg. 2013;30:293-301 pubmed publisher
    ..The aim of this study was to identify those factors which influence survival during the era of preoperative chemotherapy in patients undergoing resection of CRLM in a UK centre...
  37. Shibutani M, Noda E, Maeda K, Nagahara H, Ohtani H, Hirakawa K. Low expression of claudin-1 and presence of poorly-differentiated tumor clusters correlate with poor prognosis in colorectal cancer. Anticancer Res. 2013;33:3301-6 pubmed
    ..The aim of this study was to determine the clinical significance of claudin-1 in terms of the cell-cell adhesion, considering the poorly-differentiated tumor component...
  38. Karagkounis G, Torbenson M, Daniel H, Azad N, Diaz L, Donehower R, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119:4137-44 pubmed publisher
    ..In this study, the incidence and prognostic significance of KRAS and BRAF mutations were determined in patients undergoing surgical therapy of colorectal liver metastases (CRLM)...
  39. Gylfe A, Katainen R, Kondelin J, Tanskanen T, Cajuso T, Hänninen U, et al. Eleven candidate susceptibility genes for common familial colorectal cancer. PLoS Genet. 2013;9:e1003876 pubmed publisher
    ..Additional genetic validation in other populations is required to provide firm evidence for causality, as well as to characterize the natural history of the respective phenotypes...
  40. Miyauchi T, Yaguchi T, Kawakami Y. Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40:54-59 pubmed publisher
    ..Besides the microsatellite status, inter-patient heterogeneity in response to tumor immunity includes hypermutator phenotype, which is driven by POLE mutation, intrinsic cytokine production, and microbiota in the gut...
  41. Jin L, Vu T, Yuan G, Datta P. STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway. Cancer Res. 2017;77:5464-5478 pubmed publisher
    ..Overall, our findings illuminated a novel STRAP-NOTCH1-HES1 molecular axis as a CSC regulator in colorectal cancer, with potential implications to improve treatment of this disease. Cancer Res; 77(20); 5464-78. ©2017 AACR. ..
  42. Li P, Xiao Z, Braciak T, Ou Q, Chen G, Oduncu F. Systematic immunohistochemical screening for mismatch repair and ERCC1 gene expression from colorectal cancers in China: Clinicopathological characteristics and effects on survival. PLoS ONE. 2017;12:e0181615 pubmed publisher
    ..We also found the determination of ERCC1 expression to be useful for predicting DFS or OS for stage II and III CRC patients. In addition, the expression of MMR genes and ERCC1 showed a significant relationship. ..
  43. Hope C, Emmerich P, Papadas A, Pagenkopf A, Matkowskyj K, Van De Hey D, et al. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. J Immunol. 2017;199:1933-1941 pubmed publisher
    ..Our findings provide a rationale for testing VCAN proteolysis as a predictive and/or prognostic immune biomarker and VCAN-derived matrikines as novel immunotherapy agents. ..
  44. Sadetzki S, Chetrit A, Freedman L, Hakak N, Barchana M, Catane R, et al. Cancer risk among Holocaust survivors in Israel-A nationwide study. Cancer. 2017;123:3335-3345 pubmed publisher
    ..Holocaust survivors during World War II were exposed to various factors that are associated with cancer risk. The objective of this study was to determine whether Holocaust survivors had an increased risk for developing cancer...
  45. Arpalahti L, Hagstrom J, Mustonen H, Lundin M, Haglund C, Holmberg C. UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer. Tumour Biol. 2017;39:1010428317716078 pubmed publisher
    ..In conclusion, UCHL5 is a promising novel prognostic marker in lymph-node-positive rectal cancer. Our results also advance the currently limited knowledge of biomarkers in colorectal cancer treatment. ..
  46. Karim S, Nanji S, Brennan K, Pramesh C, Booth C. Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice. Eur J Surg Oncol. 2017;43:1481-1487 pubmed publisher
    ..A randomized controlled trial is warranted to evaluate whether chemotherapy following resection of CRCPM is associated with improved survival. ..
  47. Crespo M, Vilar E, Tsai S, Chang K, Amin S, Srinivasan T, et al. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat Med. 2017;23:878-884 pubmed publisher
    ..These studies provide an efficient strategy for deriving human COs, which can be used in disease modeling and drug discovery for colorectal disease...
  48. Peng Y, Lin C, Sung F. The association between cholecystectomy and colorectal neoplasm in inflammatory bowel diseases: A population-based cohort study. PLoS ONE. 2017;12:e0177745 pubmed publisher
    ..Inflammatory bowel diseases (IBD) and cholecystectomy are associated with the risk of colorectal cancer (CRC). Our aim was to determine the association between cholecystectomy and the CRC risk in IBD...
  49. Shinohara H, Kuranaga Y, Kumazaki M, Sugito N, Yoshikawa Y, Takai T, et al. Regulated Polarization of Tumor-Associated Macrophages by miR-145 via Colorectal Cancer-Derived Extracellular Vesicles. J Immunol. 2017;199:1505-1515 pubmed publisher
    ..These findings suggest that colorectal cancer cells use miR-145 within EVs to efficiently modulate M2-like macrophage polarization and tumor progression. ..
  50. Wang J, Mouradov D, Wang X, Jorissen R, Chambers M, Zimmerman L, et al. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. Gastroenterology. 2017;153:1082-1095 pubmed publisher
    ..Our integrative proteogenomic analysis highlights the potential of proteome profiling to inform personalized cancer medicine. ..
  51. Juneja M, Kobelt D, Walther W, Voss C, Smith J, Specker E, et al. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1. PLoS Biol. 2017;15:e2000784 pubmed publisher
    ..This is-to the best of our knowledge-the first identification of inhibitors restricting cancer progression and metastasis via the novel target MACC1. This drug repositioning might be of therapeutic value for CRC patients. ..
  52. Tan W, Dorajoo S, Chee M, Tan W, Foo F, Tang C, et al. A Novel Derivation Predicting Survival After Primary Tumor Resection in Stage IV Colorectal Cancer: Validation of a Prognostic Scoring Model and an Online Calculator to Provide Individualized Survival Estimation. Dis Colon Rectum. 2017;60:895-904 pubmed publisher
    ..A prognostic scoring model has been devised previously to predict survival following primary tumor resection in patients with metastatic colorectal cancer and unresectable metastases. This has yet to be validated...
  53. Gu D, Szallasi A. Thrombocytosis Portends Adverse Prognosis in Colorectal Cancer: A Meta-Analysis of 5,619 Patients in 16 Individual Studies. Anticancer Res. 2017;37:4717-4726 pubmed
    ..Thrombocytosis portends adverse prognosis in CRC, and may serve as a clinically useful marker to facilitate risk stratification and guide postoperative management. ..